Aeglea BioTherapeutics - AGLE Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AGLE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGLE, but not buy additional shares or sell existing shares.
View AGLE analyst ratings or view top-rated stocks.

6 analysts have issued 12 month price targets for Aeglea BioTherapeutics' shares. Their AGLE share price forecasts range from $1.00 to $3.00. On average, they predict the company's stock price to reach $1.63 in the next twelve months. This suggests a possible upside of 219.5% from the stock's current price.
View analysts price targets for AGLE or view top-rated stocks among Wall Street analysts.

Aeglea BioTherapeutics' stock was trading at $4.75 on January 1st, 2022. Since then, AGLE shares have decreased by 89.3% and is now trading at $0.5086.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our AGLE earnings forecast.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01. The biotechnology company earned $0.63 million during the quarter, compared to the consensus estimate of $1.42 million. Aeglea BioTherapeutics had a negative net margin of 1,244.84% and a negative trailing twelve-month return on equity of 105.49%.

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA).

(AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGLE stock can currently be purchased for approximately $0.51.

Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $31.11 million and generates $18.74 million in revenue each year. The biotechnology company earns $-65,800,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

The company employs 101 workers across the globe.

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121.